Revision as of 04:18, 2 January 2025 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,846 edits created drug stubTag: nowiki added | Latest revision as of 00:51, 3 January 2025 edit undoGraeme Bartlett (talk | contribs)Administrators249,851 edits chemspider | ||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{{Orphan|date=January 2025}} | |||
{{cs1 config|name-list-style=vanc|display-authors=6}} | {{cs1 config|name-list-style=vanc|display-authors=6}} | ||
{{Infobox drug | {{Infobox drug | ||
Line 18: | Line 20: | ||
| widthR = | | widthR = | ||
| altR = | | altR = | ||
| captionLR = |
| captionLR = | ||
<!-- Clinical data --> | <!-- Clinical data --> | ||
Line 39: | Line 41: | ||
| ATC_prefix = | | ATC_prefix = | ||
| ATC_suffix = | | ATC_suffix = | ||
| ATC_supplemental = |
| ATC_supplemental = | ||
<!-- Legal status --> | <!-- Legal status --> | ||
Line 60: | Line 62: | ||
| legal_UN = | | legal_UN = | ||
| legal_UN_comment = | | legal_UN_comment = | ||
| legal_status = |
| legal_status = | ||
<!-- Pharmacokinetic data --> | <!-- Pharmacokinetic data --> | ||
Line 70: | Line 72: | ||
| elimination_half-life = | | elimination_half-life = | ||
| duration_of_action= | | duration_of_action= | ||
| excretion = |
| excretion = | ||
<!-- Identifiers --> | <!-- Identifiers --> | ||
Line 79: | Line 81: | ||
| IUPHAR_ligand = | | IUPHAR_ligand = | ||
| DrugBank = | | DrugBank = | ||
| ChemSpiderID = | | ChemSpiderID = 129431709 | ||
| UNII = 3J6FQ6W4NQ | | UNII = 3J6FQ6W4NQ | ||
| KEGG = | | KEGG = | ||
Line 102: | Line 104: | ||
| melting_high = | | melting_high = | ||
| melting_notes = | | melting_notes = | ||
| boiling_point = | |||
| boiling_notes = | |||
| solubility = | | solubility = | ||
| sol_units = | | sol_units = | ||
Line 123: | Line 123: | ||
] | ] | ||
] | ] | ||
{{pharma-stub}} | {{pharma-stub}} |
Latest revision as of 00:51, 3 January 2025
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (January 2025) |
Pharmaceutical compound
Clinical data | |
---|---|
Other names | AS-1763 |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C35H39FN6O9S2 |
Molar mass | 770.85 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Docirbrutinib is an investigational new drug that is being evaluated for the treatment of cancer. It is a selective Bruton's tyrosine kinase (BTK) inhibitor that targets chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
References
- Kawahata W, Asami T, Kiyoi T, Irie T, Kashimoto S, Furuichi H, et al. (October 2021). "Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase". Journal of Medicinal Chemistry. 64 (19): 14129–14141. doi:10.1021/acs.jmedchem.1c01279. PMID 34529443.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |